Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b placebo-controlled trial of CAM2056 semaglutide depot in adults with obesity or overweight
2026-526951-79-00Phase 2Authorised
- Sponsor
- Camurus
- Start
- Oct 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CAM2056 in obesity and Overweight (3 arms), sponsored by Camurus. Primary endpoint: Relative change in body weight from baseline to Week 36. Planned start Oct 2026; status: authorised.
02
Drugs
CAM2056
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on 2026-526951-79-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526951-79-00.